PE20050579A1 - Derivados de quinolina-4-carboxilico como antagonistas de la selectina - Google Patents

Derivados de quinolina-4-carboxilico como antagonistas de la selectina

Info

Publication number
PE20050579A1
PE20050579A1 PE2004001095A PE2004001095A PE20050579A1 PE 20050579 A1 PE20050579 A1 PE 20050579A1 PE 2004001095 A PE2004001095 A PE 2004001095A PE 2004001095 A PE2004001095 A PE 2004001095A PE 20050579 A1 PE20050579 A1 PE 20050579A1
Authority
PE
Peru
Prior art keywords
quinoline
alkyl
chlorobenzyl
hydroxy
carboxyl acid
Prior art date
Application number
PE2004001095A
Other languages
English (en)
Inventor
Silvano L Debernardo
Kristin M Janz
Raymond T Camphausen
Neelu Kaila
Patricia W Bedard
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20050579A1 publication Critical patent/PE20050579A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE, L ES CO2H, UN ESTER DEL MISMO O UN ACIDO MIMETICO FARMACEUTICAMENTE ACEPTABLE; Y ES O, (CR3R4)p o NR5; P ES DE 1 A 3; X ES H, OH, OR3, ENTRE OTROS; R1, R2, R3 Y R4 SON H , ALQUILO C1-C6, PERHALOALQUILO C1-C6, CN, OH, SH, PO3R6R7, (CH2)nSO2NR8R9, ENTRE OTROS; R6 Y R7 ES H Y ALQUILO C1-C6; CADA R5, R8 Y R9 ES H, ALQUILO C1-C6, HALOAQUILO C1-C6, ENTRE OTROS ; R10 Y R11 SON H Y C1-C6; R12 ES H, ALQUILO C1-C6, PERHALOALQUILO C1-C6 , ENTRE OTROS; Z ES ARILO, ARILALQUILO, HETEROARILO. SON COMPUESTOS PREFERIDOS: ACIDO 2-(4-CLOROBENCIL)-3-HIDROXI-8-TRIFLUOROMETIL-QUINOLINA-4-CARBOXILICO; ACIDO 2-(4-CLOROBENCIL)-3-HIDROXI-8-TRIFLUOROMETOXI-QUINOLINA-4-CARBOXILICO;ACIDO 2-(4-CLOROBENCIL)-3-HIDROXI-8-ISOPROPILQUINOLINA-4-CARBOXILICO; ENTRE OTROS. SE REFIERE TAMBIEN AUN PROCESO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS ACTUAN COMO ANTAGONISTAS DE LAS PROTEINAS DE ADHESION CONOCIDAS COMO SELECTINAS
PE2004001095A 2003-11-10 2004-11-09 Derivados de quinolina-4-carboxilico como antagonistas de la selectina PE20050579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51895003P 2003-11-10 2003-11-10

Publications (1)

Publication Number Publication Date
PE20050579A1 true PE20050579A1 (es) 2005-09-08

Family

ID=34590327

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001095A PE20050579A1 (es) 2003-11-10 2004-11-09 Derivados de quinolina-4-carboxilico como antagonistas de la selectina

Country Status (21)

Country Link
US (2) US7465799B2 (es)
EP (1) EP1682511A2 (es)
JP (1) JP2007510742A (es)
KR (1) KR20060108666A (es)
CN (1) CN1902179A (es)
AR (1) AR046704A1 (es)
AU (1) AU2004288800A1 (es)
BR (1) BRPI0416357A (es)
CA (1) CA2544693A1 (es)
CO (1) CO5690556A2 (es)
CR (1) CR8384A (es)
EC (1) ECSP066558A (es)
GT (1) GT200400232A (es)
IL (1) IL175389A0 (es)
NO (1) NO20062348L (es)
PA (1) PA8617101A1 (es)
PE (1) PE20050579A1 (es)
RU (1) RU2006120450A (es)
TW (1) TW200526583A (es)
WO (1) WO2005047257A2 (es)
ZA (1) ZA200603683B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465798B2 (en) * 2003-11-10 2008-12-16 Wyeth Methods and compositions for selectin inhibition
WO2007022946A1 (de) * 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
US20080125454A1 (en) * 2006-10-05 2008-05-29 Wyeth Methods and Compositions for Treatment of Scleritis and Related Disorders
CN101646652A (zh) * 2007-03-30 2010-02-10 惠氏公司 用于选择素抑制的喹啉衍生物和包含喹啉衍生物的医药组合物
WO2008121805A1 (en) 2007-03-30 2008-10-09 Wyeth Methods and compositions for selectin inhibition
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
AU1804299A (en) * 1997-12-08 1999-06-28 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AU2002345796A1 (en) 2001-06-26 2003-03-03 Beth Israel Deaconess Medical Center Compositions and methods for inhibiting platelet activation and thrombosis
CA2453060C (en) * 2001-07-06 2011-02-08 Nippon Kayaku Kabushiki Kaisha Dye-sensitized photoelectric conversion device

Also Published As

Publication number Publication date
NO20062348L (no) 2006-08-01
CN1902179A (zh) 2007-01-24
WO2005047257A2 (en) 2005-05-26
JP2007510742A (ja) 2007-04-26
TW200526583A (en) 2005-08-16
AU2004288800A1 (en) 2005-05-26
GT200400232A (es) 2005-09-14
PA8617101A1 (es) 2006-09-22
CA2544693A1 (en) 2005-05-26
EP1682511A2 (en) 2006-07-26
ECSP066558A (es) 2006-10-17
ZA200603683B (en) 2008-05-28
US7465799B2 (en) 2008-12-16
IL175389A0 (en) 2006-09-05
WO2005047257A3 (en) 2005-07-07
CO5690556A2 (es) 2006-10-31
KR20060108666A (ko) 2006-10-18
AR046704A1 (es) 2005-12-21
US20050101568A1 (en) 2005-05-12
RU2006120450A (ru) 2007-12-27
CR8384A (es) 2006-12-07
BRPI0416357A (pt) 2007-05-08
US20090076077A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
EA200401431A1 (ru) Производные триазола в качестве антагонистов рецептора тахикинина
HRP20020175B1 (en) N-heterocyclikc derivatives as nos inhibitors
PE20051039A1 (es) [1,8] naftiridin-2-onas y compuestos relacionados
RU2007147339A (ru) Новые производные 2-азетидинона, полезные в лечении гиперлипидемических состояний
AR062937A1 (es) Compuestos que modulan el receptor cb2
CO5580746A2 (es) Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina
CO5251463A1 (es) Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos
PE20020406A1 (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS 2,6-DISUSTITUIDAS COMO INHIBIDORES DE LAS PROTEINAS CINASAS
RU2007147346A (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
NO20053974L (no) Tienopyrimidinforbindelser og anvendelse derav.
NO2012021I1 (no) Perampanel eller salter eller hydrater derav
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
RU2009105669A (ru) Способ получения 3-замещенных 2-амино-5-галогенбензамидов
RU2010133903A (ru) Способ и промежуточные соединения для получения производных 5-бифенил-4-ил-2-метилпентановой кислоты
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
NO20081056L (no) Nye, heterosykliske NF-kB-inhibitorer
EA201070437A2 (ru) Способ получения 2'-дезокси -5-азацитидина (децитабина)
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
PE55298A1 (es) Derivados de pirrolopirrolona
PE20050579A1 (es) Derivados de quinolina-4-carboxilico como antagonistas de la selectina
RU2000100785A (ru) Пиримидиноновые соединения, фармацевтические композиции, содержащие эти соединения, и способ их получения
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
RU2014129937A (ru) Способы и промежуточные соединения для получения фармацевтических агентов
EA200301317A1 (ru) Производные аминохинолина и его применение в качестве лигандов аденозина a3

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed